PLX7904

Target: This ligand targets BRAF kinase, including the V600E mutant form in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for BRAF kinase, including the V600E mutant form. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings BRAF kinase into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated PLK1 Degradation: PLX7904 can be used as a ligand component to assemble PROTACs aimed at inducing selective degradation of PLK1, a key mitotic kinase. In PROTAC formats, ligand engagement recruits the E3 ligase machinery, promoting ubiquitination and proteasomal turnover to probe mitotic control and dependency.

• Mitotic Checkpoint Mechanism Studies: By leveraging PLX7904 within targeted protein degradation constructs, researchers can dissect how PLK1 removal reshapes spindle assembly, chromosome segregation, and checkpoint signaling. This approach supports cause-and-effect experiments that distinguish degradation phenotypes from transient kinase inhibition, enabling refined mapping of mitotic pathway dependencies.

• E3 Ligase Recruitment Optimization: PLX7904-based PROTACs can be engineered with different E3 ligase recruiters to evaluate how ubiquitin ligase selection influences degradation efficiency, kinetics, and cellular selectivity. Systematic linker and orientation tuning can help identify configurations that maximize PLK1 ubiquitination and downstream mitotic phenotypes.

• Comparative Degrader vs Inhibitor Profiling: PLX7904-derived PROTACs enable side-by-side comparisons with conventional PLK1 inhibitors to quantify differences in target residence, pathway rewiring, and functional outcomes. Such studies can clarify whether observed anti-mitotic effects arise from sustained protein loss rather than catalytic blockade alone.

• Resistance and Pathway Rewiring Analysis: Incorporating PLX7904 into PROTACs supports investigations into resistance mechanisms that emerge under sustained PLK1 depletion. Researchers can monitor compensatory signaling, changes in ubiquitin-proteasome engagement, and shifts in mitotic network robustness to understand how cells adapt to targeted degradation.

PLX7904 is a RAF kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of PLX7904 is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.